After directly comparing two PD-L1 antibodies, Joseph et al. found that 89 % of the tested RCCs with sarcomatoid differentiation showed concordance in terms of PD-L1 positivity and that 50 % (13/26) of RCCs with sarcomatoid differentiation displayed coexpression of PD-L1 on neoplastic cells and contained PD-1-positive tumor-infiltrating lymphocytes.7 Here, CD274 is linked to neoplasm.